Open-Label, Safety Study of Lofexidine

Summary

The purpose of this Phase 3 open-label treatment study is to evaluate the safety and effectiveness of lofexidine at a clinically relevant dose to alleviate symptoms of acute withdrawal from any opioid, including methadone and buprenorphine. This study will take place in a variety of clinical scenarios, both in-clinic and outpatient settings.

Timeline

Start

2015-02

Primary completion

2015-09

Completion

2015-10

Drugs

Indications